Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

• Register: ClinicalTrials.gov
• Last refreshed on: 4 March 2024
• Main ID: NCT05700630
• Date of registration: 09/12/2022
• Prospective Registration: Yes
• Primary sponsor: Masonic Cancer Center, University of Minnesota
• Public title: Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia
• Scientific title: MT2022-06: Phase I Study of FT538 Monotherapy and in Combination With Vorinostat for the Treatment of Persistent Low-Level HIV Viremia
• Date of first enrolment: July 15, 2024
• Target sample size: 0
• Recruitment status: Withdrawn
• URL: https://clinicaltrials.gov/ct2/show/NCT05700630
• Study type: Interventional
• Study design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1

Countries of recruitment

United States

Key inclusion & exclusion criteria

Inclusion Criteria:

- Male or female, age =18 and =65 years at the time of signing the consent form

- HIV-1 infection on continuous antiretroviral therapy (ART) for at least 12 months
without any interruptions of greater than 14 consecutive days and without plans to
modify ART before the End of Treatment visit.

- Two or more consecutive detectable HIV RNA levels of =200 copies/mL in the last 2
years, with at least one determination meeting this criterion in the previous 12
months. (If testing was not obtained within 42 days of planned dose 1, test will be
repeated during subject screening to confirm status)

- Screening CD4+ T cell count =350 cells/ µl within 28 days of the 1st dose of FT538.

- Completion of initial COVID-19 vaccination series and/or documented COVID-19 infection
with completion of treatment = 3 months prior

- Patient weight of = 50 kg due to FT538 fixed cell dosing and FT538 product pre-dosed
packaging.

Adequate organ function within 14 days of Day 1, defined as the following:

- Platelet counts >150,000/mm^3

- Hemoglobin > 12.5 g/dL for men and > 11.5 g/dL for women. It is not acceptable for
patients to be transfused within the prior month to meet this requirement. The use of
Epogen is permitted.

- AST and ALT = 3 x upper limit of institutional normal

- Estimated CrCl (eGFR) >50 mL/min/1.73m^2

- Persons of childbearing potential or with partners of childbearing potential must be
willing to abstain from heterosexual activity or to use a highly effective form of
contraception from the time of study enrollment through at least 4 months after the
last dose of FT538. Persons are considered of childbearing potential unless: they are
postmenopausal; are surgically sterile; or they have a congenital or acquired
condition that prevents childbearing. NOTE: Abstinence is acceptable if this is the
usual lifestyle and preferred contraception.

For Dose Cohort 4 (FT538 plus Vorinostat):

- Females of childbearing potential must use highly effective contraception from the
time of study enrollment through 6 months after the last dose of vorinostat.

- Males with partners of childbearing potential must use highly effective contraception
from the time of study enrollment through 3 months after the last dose of vorinostat
or 4 months after the last dose of FT538, whichever is more conservative.

- Must agree to and sign the consent for the Master Long-Term Follow-Up study to fulfill
the FDA recommended 15 years following exposure to the investigational gene therapy
product.

- Voluntary written consent prior to the performance of any research related procedures.

Exclusion Criteria:

- Pregnant, breastfeeding, or unwilling to practice birth control for a minimum of 4
months after the last dose of FT538. If of childbearing potential, a negative
pregnancy test is required within 14 days prior to the 1st dose of FT538 or within 7
days prior to the 1st dose of vorinostat if treated in Dose Cohort 4.

- Known allergy to the following FT538 components: albumin (human) or DMSO.

- Currently receiving or likely to require systemic immunosuppressive therapy (e.g.,
prednisone >5 mg daily) for any reason within 5 days before the 1st dose of FT538 and
14 days after the last dose of FT538 - inhaled and topical steroids are permitted.

- Active or recent malignancy requiring systemic chemotherapy or surgery in the
preceding 36 months or for whom such therapies are expected in the subsequent 12
months - minor surgical removal of localized skin cancers (squamous cell carcinoma,
basal cell carcinoma) is permitted.

- Prior history of solid organ transplant or hematopoietic stem cell transplant.

- Receipt of any investigational agent (not approved by the FDA for any indication)
within 28 days prior to the first dose of FT538. Note that participation in prior HIV
cure studies, including those involving IL-2 or N803, is permitted as long as
experimental therapy completed >28 days prior.

- Chronic liver disease defined as Class B and C on the Child-Pugh scale.

- Active and poorly controlled atherosclerotic cardiovascular disease (ASCVD), as
defined by 2013 ACC/AHA guidelines, including a previous diagnosis of any of the
following within the previous 12 months: (a) acute myocardial infarction, (b) acute
coronary syndromes, (c) stable or unstable angina, (d) coronary or other arterial
revascularization, (e) stroke, (f) transient ischemic attack (TIA), or (g) peripheral
arterial disease presumed to be of atherosclerotic origin.

- Moderate-severe obstructive lung disease. In subjects reporting a history of mild
obstructive lung disease at screening, pulmonary function test (PFT) to be obtained
and patient excluded from study if the FEV1 is <80% of predicted.

- Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or
neurodegenerative disease or receipt of medications for these conditions in the 2-year
period leading up to study enrollment.

- Known concurrent or recent (defined as having received treatment within the last 3
months) infection with:

- Latent or active TB infection prior to completing a standard regimen of anti-TB
therapy; defined as meeting PPD criteria for TB exposure or a positive
quantiferon gold test collected at screening

- Active fungal infection requiring systemic antifungal therapy

- Chronic active hepatitis B or C. For Hepatitis B this will be defined as HBs
antigen + and for Hepatitis C this will be defined as Hepatitis C antibody
positive and Hepatitis C PCR+.

- COVID-19; defined as a positive SARS-CoV-2 PCR test at screening or a history of
COVID-19 diagnosed within the last 3 months.

- Clinical vaccination administered within 6 weeks of the 1st dose of FT538.

- Presence of any social issues that, per investigator judgement, are likely to
interfere with study conduct or may cause increased risk to patient.

- Patient history of alcohol or substance abuse that, per investigator judgement, are
likely to interfere with study conduct or may cause increased risk to patient

- Any medical condition or clinical laboratory abnormality that, per investigator
judgement, precludes safe participation in and completion of the study or that could
affect compliance with protocol conduct or interpretation of results.



Age minimum: 18 Years
Age maximum: 65 Years
Gender: All

Health Condition(s) or Problem(s) studied

Cd4+ Lymphocyte Deficiency

Interleukin

Lymphoid Tissue; Infection

ART

HIV-1-infection

Intervention(s)

Drug: Vorinostat

Biological: FT538

Primary Outcome(s)

Determine the safety and feasibility of administering FT538 monotherapy. [Time Frame: 26 months]

Secondary Outcome(s)

Characterize the toxicities associated with FT538 monotherapy and vorinostat. [Time Frame: 30 months]

Determine the impact of FT538 on the persistence of low-level HIV viremia [Time Frame: 30 months]

Secondary ID(s)

2022LS028

Source(s) of Monetary Support

Please refer to primary and secondary sponsors